[18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease
Identifieur interne : 001990 ( Main/Exploration ); précédent : 001989; suivant : 001991[18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease
Auteurs : Juha O. Rinne [Finlande] ; Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Olli Eskola [Finlande] ; Olof Solin [Finlande]Source :
- Synapse [ 0887-4476 ] ; 2001-06-01.
English descriptors
- KwdEn :
Abstract
The aim of this study was to compare two PET ligands, 6‐[18F]fluoro‐L‐dopa ([18F]FDOPA) and 18F‐labeled CFT, 2β‐carbomethoxy‐3β‐(4‐[18F]‐fluorophenyl)tropane ([18F]CFT), in detecting presynaptic dopaminergic hypofunction in early Parkinson's disease (PD). These ligands reflect different aspects of presynaptic dopaminergic function, since [18F]FDOPA mainly reflects 6‐[18F]fluorodopamine (fluorodopamine) synthesis and storage whereas [18F]CFT uptake is related to dopamine transporter function. Eight de novo patients with PD who had never been on antiparkinsonian medication were investigated with [18F]FDOPA and [18F]CFT PET. Five healthy volunteers were studied as controls. In PD patients, both [18F]FDOPA and [18F]CFT uptakes were significantly reduced both in the contralateral and ipsilateral anterior and posterior putamen. The reduction was greatest in the contralateral posterior putamen (to 28% of control mean for [18F]FDOPA, P < 0.0001 and to 16% for [18F]CFT, P < 0.0001). Individually, all patients' [18F]FDOPA and [18F]CFT uptake values in the contralateral anterior and posterior putamen were below 3 SD of the control mean. In the caudate nucleus, the mean uptake of both tracers was significantly reduced both ipsilaterally and contralaterally, but less severely than in the putamen (to 69% of the control mean for [18F]FDOPA, P = 0.003 and to 60% for [18F]CFT, P = 0.001 contralaterally). Our results show that both [18F]FDOPA as well as [18F]CFT sensitively detect presynaptic dopaminergic hypofunction in early PD. They demonstrate a considerable reduction of tracer uptake that is greatest in the posterior putamen, followed by the anterior putamen and the caudate nucleus. Synapse 40:193–200, 2001. © 2001 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/syn.1042
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">[18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease</title><author><name sortKey="O Rinne, Juha" sort="O Rinne, Juha" uniqKey="O Rinne J" first="Juha" last="O. Rinne">Juha O. Rinne</name></author><author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name></author><author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name></author><author><name sortKey="Eskola, Olli" sort="Eskola, Olli" uniqKey="Eskola O" first="Olli" last="Eskola">Olli Eskola</name></author><author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5D5662BFB4E3C9DCDDFC44ADD6665F6EFDE4029B</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/syn.1042</idno><idno type="url">https://api.istex.fr/document/5D5662BFB4E3C9DCDDFC44ADD6665F6EFDE4029B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001955</idno><idno type="wicri:Area/Main/Curation">001704</idno><idno type="wicri:Area/Main/Exploration">001990</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">[18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease</title><author><name sortKey="O Rinne, Juha" sort="O Rinne, Juha" uniqKey="O Rinne J" first="Juha" last="O. Rinne">Juha O. Rinne</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Turku PET Centre, Radiochemistry Laboratory, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Eskola, Olli" sort="Eskola, Olli" uniqKey="Eskola O" first="Olli" last="Eskola">Olli Eskola</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Turku PET Centre, Radiochemistry Laboratory, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Turku PET Centre, Radiochemistry Laboratory, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-06-01">2001-06-01</date><biblScope unit="volume">40</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="193">193</biblScope><biblScope unit="page" to="200">200</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">5D5662BFB4E3C9DCDDFC44ADD6665F6EFDE4029B</idno><idno type="DOI">10.1002/syn.1042</idno><idno type="ArticleID">SYN1042</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CFT</term><term>PET</term><term>Parkinson's disease</term><term>dopamine transporter</term><term>fluorodopa</term><term>positron emission tomography</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to compare two PET ligands, 6‐[18F]fluoro‐L‐dopa ([18F]FDOPA) and 18F‐labeled CFT, 2β‐carbomethoxy‐3β‐(4‐[18F]‐fluorophenyl)tropane ([18F]CFT), in detecting presynaptic dopaminergic hypofunction in early Parkinson's disease (PD). These ligands reflect different aspects of presynaptic dopaminergic function, since [18F]FDOPA mainly reflects 6‐[18F]fluorodopamine (fluorodopamine) synthesis and storage whereas [18F]CFT uptake is related to dopamine transporter function. Eight de novo patients with PD who had never been on antiparkinsonian medication were investigated with [18F]FDOPA and [18F]CFT PET. Five healthy volunteers were studied as controls. In PD patients, both [18F]FDOPA and [18F]CFT uptakes were significantly reduced both in the contralateral and ipsilateral anterior and posterior putamen. The reduction was greatest in the contralateral posterior putamen (to 28% of control mean for [18F]FDOPA, P < 0.0001 and to 16% for [18F]CFT, P < 0.0001). Individually, all patients' [18F]FDOPA and [18F]CFT uptake values in the contralateral anterior and posterior putamen were below 3 SD of the control mean. In the caudate nucleus, the mean uptake of both tracers was significantly reduced both ipsilaterally and contralaterally, but less severely than in the putamen (to 69% of the control mean for [18F]FDOPA, P = 0.003 and to 60% for [18F]CFT, P = 0.001 contralaterally). Our results show that both [18F]FDOPA as well as [18F]CFT sensitively detect presynaptic dopaminergic hypofunction in early PD. They demonstrate a considerable reduction of tracer uptake that is greatest in the posterior putamen, followed by the anterior putamen and the caudate nucleus. Synapse 40:193–200, 2001. © 2001 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Finlande occidentale</li></region><settlement><li>Turku</li></settlement><orgName><li>Université de Turku</li></orgName></list><tree><country name="Finlande"><region name="Finlande occidentale"><name sortKey="O Rinne, Juha" sort="O Rinne, Juha" uniqKey="O Rinne J" first="Juha" last="O. Rinne">Juha O. Rinne</name></region><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name><name sortKey="Eskola, Olli" sort="Eskola, Olli" uniqKey="Eskola O" first="Olli" last="Eskola">Olli Eskola</name><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001990 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001990 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5D5662BFB4E3C9DCDDFC44ADD6665F6EFDE4029B
|texte= [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |